Showing 1601-1610 of 1732 results for "".
- Effects of COVID-19 on Stroke Presentation & Severity Are Globally Verifiedhttps://practicalneurology.com/news/high-mortality-seen-with-hemorrhagic-but-not-ischemic-stroke-in-those-critically-ill-with-covid-19/2469557/In what may be one of the largest collaborations and observational studies conducted to date, data from 6 continents, 70 countries, and 457 stroke centers were analyzed to evaluate incidence in stroke during the first 4 months of and the last 4 months before the COVID-19 pandemic. Diagnoses were
- Wearable Migraine Device Can Be Prescribed Through Telemedicine Platformhttps://practicalneurology.com/news/wearable-migraine-device-can-be-prescribed-through-telemedicine-platform/2469220/A prescribed wearable device (Nerivio, Theranica, Montcliar, NJ) made for treatment of migraine and other pain conditions is now available on a telemedicine platform (UpScript, Scotsdale, AZ). The FDA-authorized device worn on one’s arm and utilizes electronic pulses controlled by a smartph
- Artificial Intelligence Analyses of Blood Samples Predicts Neurodegenerative Disease Progressionhttps://practicalneurology.com/news/artificial-intelligence-analyses-blood-samples-to-predict-neurodegenerative-disease-progression/2469141/A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain neurodegenerative disease progression. The AI analysis could one day help doctors choose more appropriate and effective treatments for individuals who see them. Researchers at The Neu
- Pimavanserin Reduce Risks of Dementia-Related Psychotic Relapse Almost Threefoldhttps://practicalneurology.com/news/pimavanserin-reduce-risks-of-dementia-related-psychotic-relapse-almost-threefold/2469089/In top-line results from the pivotal phase 3 HARMONY (NCT03325556) study, treatment with pimavanserin vs placebo (Nuplazid, Acadia Pharmaceuticals, San Diego, CA) reduced risk of psychotic relapse by 2.8 fold (HR = 0.353; one-sided
- $1.5 Million in Community Grant Funding from The Parkinson's Foundationhttps://practicalneurology.com/news/15-million-in-community-grant-funding-from-the-parkinsons-foundation/2468771/More than $1.5 million in community grants from The Parkinson's Foundation were announced. The grants will support education, wellness, and local health programs that address unmet needs for people living with Parkinson’s disease (PD) and their loved ones. The grants range from $5,000 t
- A Wide Range of Cenobamate Doses Linked to Seizure Freedomhttps://practicalneurology.com/news/a-wide-range-of-cenobamate-doses-linked-to-seizure-freedom/2470656/Flexible dosing with Xcopri (cenobamate; SK Life Science, Paramus, NJ) may allow for optimal seizure reduction, according to data presented at the American Epilepsy Society (AES) 2024 Annual Meeting. Results from the post-hoc analysis of an open-label, phase 3 study demonstrate that a wide range
- Once-Daily Pill Approved to Treat Forms of Astrocytoma and Oligodendrogliomahttps://practicalneurology.com/news/once-daily-pill-approved-to-treat-forms-of-astrocytoma-and-oligodendroglioma/2470553/The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib; Servier, Boston, MA) for the treatment of adults and children aged ≥12 years with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutati
- Eisai Initiates Formal Application for Subcutaneous Leqembi Alzheimer Disease Treatmenthttps://practicalneurology.com/news/eisai-initiates-formal-application-for-subcutaneous-leqembi-alzheimer-disease-treatment/2470474/Eisai announced the initiation of the rolling submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for Leqembi (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA) subcutaneous (SC) autoinjector for weekly maintenance dosing to treat individuals wi
- Dr. Anthony Lang Presents Novel SynNeurGe Model of Parkinson Disease Identificationhttps://practicalneurology.com/news/dr-anthony-lang-presents-novel-synneurge-model-of-parkinson-disease-identification/2470321/Dr. Anthony Lang, Professor of Neurology and Jack Clark Chair for Parkinson’s Disease Research at the University of Toronto, presented a new model for identifying Parkinson disease (PD) at the 26th World Congress of Neurology. The new model, SynNeurGe, is a framework consisting of 3 distinc
- FDA Clears Orally Inhaled DHE Formulation for Clinical Investigation as Potential Treatment for Acute Migrainehttps://practicalneurology.com/news/fda-clears-orally-inhaled-dhe-formulation-for-clinical-investigation-as-potential-treatment-for-acute-migraine/2470301/Pulmatrix’s (Bedford, MA) investigational new drug (IND) application for PUR3100 (dihydroergotamine [DHE] mesylate inhalation powder) has been cleared by the Food and Drug Administration (FDA), authorizing further investigation into this potential therapy for acute migraine. PUR3100 consist